Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community.
BACKGROUND
Prevalence of physical comorbidity in severe mental illness is a significant public health concern, but comparative data in people with diagnoses other than schizophrenia are sparse.


OBJECTIVE
To investigate the prevalence of metabolic disease and cardiovascular risk in people with severe mental illness treated with antipsychotics in the community.


METHODS
Case-control study of 90 people treated with antipsychotics in the community and 92 age- and gender-matched controls. The prevalence of metabolic syndrome and 10-year cardiovascular risk were calculated.


RESULTS
People on antipsychotics had a significantly worse metabolic profile than controls (F=6.583, d.f.=15,161, P<0.0001). Moreover, metabolic syndrome was more prevalent (OR=3.68, 95% CI 1.71-7.93, P=0.001), as was cardiovascular risk across a number of outcomes. These results are consistent across diagnostic groups.


CONCLUSIONS
People with severe mental illness treated with antipsychotics have excess metabolic dysfunction and heightened risk for cardiovascular disease.
Mackin
Paul
P
School of Neurology, Neurobiology and Psychiatry, University of Newcastle upon Tyne, Leazes Wing (Psychiatry), Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK. paul.mackin@ncl.ac.uk
Bishop
David
D
Watkinson
Helen
H
Gallagher
Peter
P
Ferrier
I Nicol
IN
D000328:Adult; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D016022:Case-Control Studies; D003153:Community Health Services; D015897:Comorbidity; D005260:Female; D006801:Humans; D008297:Male; D008659:Metabolic Diseases / Q000453:epidemiology*; D008875:Middle Aged; D015995:Prevalence; D011618:Psychotic Disorders / Q000188:drug therapy / Q000453:epidemiology*; D012306:Risk; D012907:Smoking / Q000009:adverse effects; D006113:United Kingdom / Q000453:epidemiology
D014150:Antipsychotic Agents